Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company raising $3 million for medicinal cannabis

The company is preparing to start a pilot cannabis growing program.
cannabis growing facility
Growing facility in Queensland is well advanced

The Hydroponics Company (ASX:THC) will close its share purchase plan after subscriptions for the well-received offer reaches $3 million. The offer price is $0.63 per share.

The funds raised will be applied to progress the company’s domestic development of medicinal cannabis, further investment into Canadian assets, and to provide working capital.

READ: The Hydroponics Company gets a lift following medicinal cannabis export approval

The company’s share price has increased 38% to $0.94 since the start of the year, underpinned by the federal government’s decision to allow medicinal cannabis to be exported from Australia.

The government has approved the exportation of medicinal cannabis in a bid to strengthen the supply of medicinal cannabis amid growing demand domestically and worldwide.

Pilot growing program in the first half of 2018

The Hydroponics Company is on track for a pilot cannabis growing program targeted for the first half of 2018, subject to government licencing.

Significantly, the build out of the company’s growing facility in Queensland is well advanced.

Medicinal cannabis clinics program to commence in 2018

Early this year, the company will commence recruitment of staff for the expansion of the National Access Cannabis (NAC) clinic model.

The clinics will provide professional education and training for referring physicians and patients, and, in parallel collect meaningful patient data to support further advancement of the program.

READ: The Hydroponics Company’s shares surge after signing medicinal cannabis deal

The Hydroponics Company is on track to import the first medicinal cannabis product range from Endoca early this year.

Endoca is one of Europe’s most highly respected suppliers of certified medicinal cannabis, with sales exceeding €50 million per annum.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
1530537220_Blood-Test.jpg
July 03 2018
The research and diagnostic company develops cancer-detecting blood tests
pipette and petri dish
June 20 2018
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use